Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769487 | 0.92 | BACE1 (0.41) | BACE1KDM1AHDAC4 | |
| Hydrochloric Acid SCHEMBL18742552 | 0.91 | BACE1 (0.40) | BACE1 | |
| SCHEMBL12479985 | 0.83 | BACE1 (0.40) | BACE1KDM1AHDAC4HDAC6TAAR1 | |
| Hydrochloric Acid SCHEMBL13837425 | 0.82 | BACE1 (0.40) | BACE1KDM1AHDAC4HDAC6TAAR1 | |
| SCHEMBL25156642 | 0.79 | KDM1A (0.41) | KDM1ATAAR1 | |
| SCHEMBL30344161 | 0.79 | KDM1A (0.41) | KDM1ATAAR1 | |
| SCHEMBL3067734 | 0.79 | HDAC4 (0.46) | HDAC4HDAC6 | |
| SCHEMBL1604324 | 0.79 | HDAC4 (0.43) | KDM1AHDAC4TAAR1 | |
| SCHEMBL30344664 | 0.79 | HDAC4 (0.43) | KDM1AHDAC4TAAR1 | |
| SCHEMBL24595849 | 0.78 | KDM1A (0.40) | KDM1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| EP-2358716-B1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME LLC | 2011-09-29 | — | — | US | disclosed |
| EP-2358716-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | Schering Corporation (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010056631-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | SCHERING CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | FABP4, FABP1, FABP3 | BACE1 1748/4885KDM1A 3234/4885HDAC4 386/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | BACE1 526/4885KDM1A 4743/4885HDAC4 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.